Business
Catheter Precision Announces the Start of Enrollment for the LockeT Compare Study
First patients have been enrolledFort Mill, S.C., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market today announced that the LockeT Compare Study has enrolled its first three patients. The LockeT Compare Study is a single center, physician-initiated study that will enroll up to 100 patients and evaluate the safety profile of the Locke
About this update from Catheter Precision, Inc.
[{"type":"image","alt":"Catheter Precision, Inc.","displaySize":"","headline":null,"caption":"Catheter Precision, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":274,"height":58,"url":"https://media.zenfs.com/en/globenewswire.com/c0002fcea5abba0697310d2b7733beb5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/YQBzazT126278wVP0b5CKA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTg5O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/c0002fcea5abba0697310d2b7733beb5","width":274,"height":58}},"lazy":false},{"type":"text","content":"First patients have been enrolled","length":33,"tagName":"p"},{"type":"text","content":"Fort Mill, S.C., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market today announced that the LockeT Compare Study has enrolled its first three patients.","length":315,"tagName":"p"},{"type":"text","content":"The LockeT Compare Study is a single center, physician-initiated study that will enroll up to 100 patients and evaluate the safety profile of the LockeT suture retention device compared to internal closure devices. Groin complications after a cardiac catheter procedure, such as atrial fibrillation, are common and can range from small bruising to serious events such as embolism. To date, LockeT clinical data has shown that the product is safe, effective and reduces procedural cost without changing current hospital practices and workflows.","length":543,"tagName":"p"},{"type":"text","content":"“Effective groin management at the access site after a cardiac catheter procedure, is just as important as the procedure outcomes,” said David Jenkins, CEO of Catheter Precision. “We have successfully shown that LockeT creates hemostasis as an external device and believe that this study will also show that there is a reduction in thrombotic episodes compared to closure devices that have an internal closure mechanism, thus improving patient safety.”","length":452,"tagName":"p"},{"type":"text","content":"About LockeTCatheter Precision’s LockeT is a suture retention device intended to assist in wound closure after percutaneous venous punctures. LockeT is a Class 1 device registered with the FDA and has received CE Mark approval.","length":228,"tagName":"p"},{"type":"...